323 related articles for article (PubMed ID: 20535785)
1. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
[TBL] [Abstract][Full Text] [Related]
2. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
[TBL] [Abstract][Full Text] [Related]
3. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Hyrich KL; Watson KD; Lunt M; ; Symmons DP;
Ann Rheum Dis; 2010 Jun; 69(6):1086-91. PubMed ID: 20444754
[TBL] [Abstract][Full Text] [Related]
4. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
5. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Hyrich KL; ; Silman AJ; Symmons DP;
Arthritis Rheum; 2007 Sep; 56(9):2905-12. PubMed ID: 17763428
[TBL] [Abstract][Full Text] [Related]
6. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
[TBL] [Abstract][Full Text] [Related]
7. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
[TBL] [Abstract][Full Text] [Related]
8. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731
[TBL] [Abstract][Full Text] [Related]
9. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
Mercer LK; Green AC; Galloway JB; Davies R; Lunt M; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2012 Jun; 71(6):869-74. PubMed ID: 22241900
[TBL] [Abstract][Full Text] [Related]
10. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
Davies R; Galloway JB; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2011 Oct; 70(10):1831-4. PubMed ID: 21784722
[TBL] [Abstract][Full Text] [Related]
11. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
[TBL] [Abstract][Full Text] [Related]
12. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
Dixon WG; Hyrich KL; Watson KD; Lunt M; Galloway J; Ustianowski A; ; Symmons DP;
Ann Rheum Dis; 2010 Mar; 69(3):522-8. PubMed ID: 19854715
[TBL] [Abstract][Full Text] [Related]
13. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Ustianowski AP; Helbert M; Watson KD; Lunt M; Symmons DP;
Ann Rheum Dis; 2011 Oct; 70(10):1810-4. PubMed ID: 21784730
[TBL] [Abstract][Full Text] [Related]
14. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
16. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
17. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Soliman MM; Ashcroft DM; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2011 Apr; 70(4):583-9. PubMed ID: 21330639
[TBL] [Abstract][Full Text] [Related]
18. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Lunt M; Watson KD; Dixon WG; ; Symmons DP; Hyrich KL;
Arthritis Rheum; 2010 Nov; 62(11):3145-53. PubMed ID: 20662063
[TBL] [Abstract][Full Text] [Related]
19. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.
Strangfeld A; Hierse F; Rau R; Burmester GR; Krummel-Lorenz B; Demary W; Listing J; Zink A
Arthritis Res Ther; 2010; 12(1):R5. PubMed ID: 20064207
[TBL] [Abstract][Full Text] [Related]
20. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.
Morgan CL; Emery P; Porter D; Reynolds A; Young A; Boyd H; Poole CD; Currie CJ
Rheumatology (Oxford); 2014 Jan; 53(1):186-94. PubMed ID: 24140761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
